Companies › Pieris Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cinrebafusp alfa (PRS-343) HER2/4-1BB bispecific antibody | ERBB2, TNFRSF9 | Phase 2 | HER2-positive Gastric Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05190445 | Cinrebafusp alfa (PRS-343) | Phase 2 | HER2-positive Gastric Cancer | Oncology | Feb 2023 |
Lyvgen Biopharma Holdings Vasgene Therapeutics Suzhou BlueHorse Therapeutics Evaxion Biotech Primmune Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.